Synergistic effect of celecoxib on TRAIL-induced apoptosis in hepatocellular carcinoma cells

Cancer Investigation

Volumn 28, Issue 6, 2010, Pages 629-634

  Lu, Guoyue ^a   Liu, Yahui ^a   Ji, Bai ^a   Wei, Feng ^a   Hao, Chunhai ^b   Wang, Guangyi ^a  

^a JILIN UNIVERSITY   (China)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

C FLIP; Caspase 8; Celecoxib; Hepatocellular Carcinoma; TRAIL

Indexed keywords

CAMPTOTHECIN; CASPASE 3; CASPASE 8; CELECOXIB; CISPLATIN; FLICE INHIBITORY PROTEIN; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL SPECIFICITY; CELL STRAIN HEPG2; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME DEGRADATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INCUBATION TIME; LIVER CELL CARCINOMA; PRIORITY JOURNAL; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CAMPTOTHECIN; CARCINOMA, HEPATOCELLULAR; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CASPASE 3; CASPASE 8; CISPLATIN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; PYRAZOLES; RECOMBINANT PROTEINS; SULFONAMIDES; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 77953179539     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357900903095631     Document Type: Article

References (26)

1. Wiley, S.R.; Schooley, K.; Smolak, P.J.; Din, W.S.; Huang, C.P.; Nicholl, J.K.; et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995, 3(6), 673-682.
2. Pitti, R.M.; Marsters, S.A.; Ruppert, S.; Donahue, C.J.; Moore, A.; Ashkenazi, A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996, 271(22), 12687-12690.
3. Ashkenazi, A.; Holland, P.; Eckhardt, S.G. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol 2008, 26(21), 3621-3630.
4. Almasan, A.; Ashkenazi, A. Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev 2003, 14(3-4), 337-348.
5. Scaffidi, C.; Medema, J.P.; Krammer, P.H.; Peter, M.E. FLICE is predominantly expressed as two functionally active isoforms, caspase-8/a and caspase-8/b. J Biol Chem 1997, 272(43), 26953-26958.
6. Irmler, M.; Thome, M.; Hahne, M.; Schneider, P.; Hofmann, K.; Steiner, V.; et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997, 388(6638), 190-195.
7. Xiao, C.; Yang, B.F.; Asadi, N.; Beguinot, F.; Hao, C. Tumor necrosis factor-related apoptosis-inducing ligand-induced death-inducing signaling complex and its modulation by c-FLIP and PED/PEA-15 in glioma cells. J Biol Chem 2002, 277(28), 25020-25025.
8. Yamanaka, T.; Shiraki, K.; Sugimoto, K.; Ito, T.; Fujikawa, K.; Ito, M.; et al. Chemotherapeutic agents augment TRAIL-induced apoptosis in human hepatocellular carcinoma cell lines. Hepatology 2000, 32(3), 482-490.
9. Ganten, T.M.; Haas, T.L.; Sykora, J.; Stahl, H.; Sprick, M.R.; Fas, S.C.; et al. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. Cell Death Differ 2004, 11(Suppl. 1), S86-S96.
10. Steinbach, G.; Lynch, P.M.; Phillips, R.K.; Wallace, M.H.; Hawk, E.; Gordon, G.B.; et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000, 342(26), 1946-1952.
11. Kern, M.A.; Schubert, D.; Sahi, D.; Schoneweiss, M.M.; Moll, I.; Haugg, A.M.; et al. Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells. Hepatology 2002, 36(4 Pt. 1), 885-894.
12. Wang, P.; Zhang, J.; Bellail, A.; Jiang, W.; Hugh, J.; Kneteman, N.M.; et al. Inhibition of RIP and c-FLIP enhances TRAIL-induced apoptosis in pancreatic cancer cells. Cell Signal 2007, 19(11), 2237-2246.
13. Song, J.H.; Wang, C.X.; Song, D.K.; Wang, P.; Shuaib, A.; Hao, C. Interferon gamma induces neurite outgrowth by upregulation of p35 neuron-specific cyclin-dependent kinase 5 activator via activation of ERK1/2 pathway. J Biol Chem 2005, 280(13), 12896-12901.
14. Ganten, T.M.; Koschny, R.; Haas, T.L.; Sykora, J.; Li-Weber, M.; Herzer, K.; et al. Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL. Hepatology 2005, 42(3), 588-597.
15. Liu, X.; Yue, P.; Zhou, Z.; Khuri, F.R.; Sun, S.Y. Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. J Natl Cancer Inst 2004, 96(23), 1769-1780.
16. Song, J.H.; Song, D.K.; Herlyn, M.; Petruk, K.C.; Hao, C. Cisplatin downregulation of cellular Fas-associated death domainlike interleukin-1beta- converting enzyme-like inhibitory proteins to restore tumor necrosis factor-related apoptosis-inducing ligandinduced apoptosis in human melanoma cells. Clin Cancer Res 2003, 9(11), 4255-4266.
17. Parkin, D.M.; Bray, F.; Ferlay, J.; Pisani, P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55(2), 74-108.
18. Skelton, M.R.; O'Neil, B. Targeted therapies for hepatocellular carcinoma. Clin Adv Hematol Oncol 2008, 6(3), 209-218.
19. Gajewski, T.F. On the TRAIL toward death receptor-based cancer therapeutics. J Clin Oncol 2007, 25(11), 1305-1307.
20. Kim, Y.S.; Schwabe, R.F.; Qian, T.; Lemasters, J.J.; Brenner, D.A. TRAIL-mediated apoptosis requires NF-kappaB inhibition and the mitochondrial permeability transition in human hepatoma cells. Hepatology 2002, 36(6), 1498-1508.
21. Liedtke, C.; Groger, N.; Manns, M.P.; Trautwein, C. Interferon-alpha enhances TRAIL-mediated apoptosis by upregulating caspase-8 transcription in human hepatoma cells. J Hepatol 2006, 44(2), 342-349.
22. Wu, G.S.; Burns, T.F.; McDonald, E.R., 3rd; Jiang, W.; Meng, R.; Krantz, I.D.; et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 1997, 17(2), 141-143.
23. Song, J.H.; Song, D.K.; Pyrzynska, B.; Petruk, K.C.; Van Meir, E.G.; Hao, C. TRAIL triggers apoptosis in malignant glioma cells through extrinsic and intrinsic pathways. Brain Pathol 2003, 13(4), 539-553.
24. Zou, W.; Liu, X.; Yue, P.; Khuri, F.R.; Sun, S.Y. PPARgamma ligands enhance TRAIL-induced apoptosis through DR5 upregulation and c-FLIP downregulation in human lung cancer cells. Cancer Biol Ther 2007, 6(1), 99-106.
25. Son, Y.G.; Kim, E.H.; Kim, J.Y.; Kim, S.U.; Kwon, T.K.; Yoon, A.R.; et al. Silibinin sensitizes human glioma cells to TRAIL-mediated apoptosis via DR5 upregulation and downregulation of c-FLIP and survivin. Cancer Res 2007, 67(17), 8274-8284.
26. Bressac, B.; Galvin, K.M.; Liang, T.J.; Isselbacher, K.J.; Wands, J.R.; Ozturk, M. Abnormal structure and expression of p53 gene in human hepatocellular carcinoma. Proc Natl Acad Sci USA 1990, 87(5), 1973-1977.